Verrica Pharmaceuticals Inc.
VRCA
$0.4905
$0.01132.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 119.31% | -134.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 119.31% | -134.40% | |||
| Cost of Revenue | 2,765.52% | -88.73% | |||
| Gross Profit | -446.98% | -268.39% | |||
| SG&A Expenses | -38.57% | -2.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.32% | -7.16% | |||
| Operating Income | 45.29% | -36.16% | |||
| Income Before Tax | 29.13% | -33.02% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 29.13% | -33.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.13% | -33.02% | |||
| EBIT | 45.29% | -36.16% | |||
| EBITDA | 45.56% | -36.83% | |||
| EPS Basic | 50.74% | -32.14% | |||
| Normalized Basic EPS | 51.00% | -32.16% | |||
| EPS Diluted | 50.74% | -32.14% | |||
| Normalized Diluted EPS | 51.00% | -32.16% | |||
| Average Basic Shares Outstanding | 43.84% | 0.65% | |||
| Average Diluted Shares Outstanding | 43.84% | 0.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||